NCT03726359
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with definitive leptomeningeal metastases, based on cerebrospinal fluid examination; Patients with prior radiotherapy treatment of the target lesions
https://ClinicalTrials.gov/show/NCT03726359